Drug Profile
SER 150
Alternative Names: EV 077; EV-077-3201-2; EV-077-3201-2TB; EV-077-3201-2TBS; SER 150 DN; SER 150 TBSLatest Information Update: 20 Jun 2022
Price :
$50
*
At a glance
- Originator Evolva Biotech
- Developer Evolva Holding SA; Serodus
- Class Anticoagulants; Antivirals; Small molecules
- Mechanism of Action Platelet aggregation inhibitors; Thromboxane receptor antagonists; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Diabetic nephropathies
- No development reported Influenza A virus infections
Most Recent Events
- 20 Jun 2022 Phase-I clinical trials in Diabetic nephropathies (PO) (Serodus pipeline, June 2022)
- 08 Sep 2021 Phase II development is ongoing in Diabetic nephropathies in Germany (PO) (Serodus pipeline, September 2021)
- 18 Aug 2021 Phase-II/III clinical trials in Diabetic nephropathies (In adults, In the elderly) in Australia (PO) (NCT04881123)